Zenosense, Inc. Provides Development Update
21 Mai 2014 - 2:30PM
Marketwired
Zenosense, Inc. Provides Development Update
VALENCIA, SPAIN--(Marketwired - May 21, 2014) - Zenosense, Inc.
(OTCQB: ZENO) ("Zenosense", the "Company"), a healthcare technology
company focused on developing and marketing a device for use in
hospitals and other healthcare settings to detect the
Methicillin-resistant Staphylococcus aureus (MRSA) "Super-Bug," is
pleased to announce that based on data and information provided by
and reviews with Zenon Biosystem considerable progress has been
made since signing the development agreement six months ago.
Development of the Company's MRSA device commenced in December,
2013. A technical review of Volatile Organic Compounds ("VOCs")
produced by Methicillin-susceptible S.aureus ("MSSA") and MRSA in
vitro or exhaled breath was undertaken. Several compounds,
including compounds that might be used to discriminate between MRSA
and MSSA, were identified as having potential utility to identify
S. aureus ("SA") from background VOCs produced by smoking and
natural flora.
A comprehensive work plan and laboratory protocols were
established using Gold Standard Gas Chromatography/Mass
Spectrometry techniques ("GC/MS") and Solid Phase Micro Extraction
("SPME") and the following testing has been successfully carried
out;
- Identifying the target VOCs in the headspace above a contained
bacterial culture;
- Correlating target VOCs with exhaled breath in infected
patients with SA; and
- Detecting those VOCs with an appropriate gas sensor.
An in-depth review has also been carried out to determine
suitable gas sensors. These sensors fall into two broad groups,
Metal Oxide ("MO") sensors and polymer based sensors. Several
different sensors of each type have been subjected to both numerous
in vitro headspace tests and exhaled breath tests using an
optimised SPME fiber VOC collection, to determine detection limits
and therefore suitability. In addition, a cost effective exhaled
breath collection technique and protocol has been developed to
assist the correlation process.
These initial tests using basic MO sensors have assessed the
response to MSSA and MRSA in headspace and exhaled breath in 14
volunteers (6 SA carriers and 8 non-carriers). The principal
component analysis indicated a sensibility and specificity of as
high as 75% and 66% respectively.
Work is underway with the intention of increasing the
sensibility and specificity by a multiple of up to 10 using a new
design Surface Acoustic Wave multiple polymer sensor. These sensors
are also low cost, of high sensitivity and stability, and have a
low power consumption compared to MO sensors.
In parallel, there has been significant development of the
complex algorithmic processing to reduce interference from
unrelated VOCs and to amplify the detection of SA specific
signature VOCs. Data obtained from the GC/MS testing continues to
be analysed to identify additional SA compounds which might be used
to detect the presence of MSSA and MRSA in exhaled breath.
The next steps will be to commence laboratory experiments with
coagulase-negative Staphylococci strains and hospital experiments
with clinical MRSA, MSSA and coagulase-negative Staphylococci
strains.
During the period collaboration agreements and partnerships have
been established with relevant hospitals, universities and a
private laboratory in the various fields of sensors, polymer
electrochemistry, microbiology, infectious disease, pneumology,
chromatography and microorganism identification.
About Zenosense, Inc.
Zenosense, Inc. is a detection device development company based
in Valencia, Spain. Its mission is develop, market and sell an
effective MRSA detector, by way of licenced-in technology, for sale
to healthcare providers for use in clinical settings. The Company
believes there is enormous latent demand for a cost-effective MRSA
detector, driven by the costs associated with the late detection of
MRSA, and that it has identified a valuable new market segment for
a wearable detection device. The development and exclusive license
agreement also includes cancer sensory devices. Find out more at
www.zenosense.net.
Forward-Looking Statements
Statements in this news release that are not statements of
historical fact are forward-looking statements, which are subject
to certain risks and uncertainties. Forward-looking statements
can often be identified by words such as "expects," "intends,"
"plans," "may," "could," "should," "anticipates," "likely,"
"believes" and words of similar import. Forward-looking
statements are based on current facts and analyses and other
information that are based on forecasts of future results,
estimates of amounts not yet determined and assumptions of
management. Actual results may differ materially from those
expressed or implied by forward-looking statements due to a variety
of factors that may or may not be foreseeable or within the
reasonable control of the Company. Readers are cautioned not
to place undue reliance on such forward-looking
statements. Additional information on risks and other factors
that may affect the business and financial results of the Company
can be found in filings of the Company with the U.S. Securities and
Exchange Commission, including without limitation the section
entitled "Risk Factors" in the Company's Annual Report on Form 10-K
for the year ended December 31, 2013 filed on filed on March 26,
2014, and in Company reports filed subsequently
thereto. Except as otherwise required by law, the Company
disclaims any obligations or undertaking to publicly release any
updates or revisions to any forward-looking statement contained in
this news release to reflect any change in the Company's
expectations with regard thereto or any change in events,
conditions or circumstances on which any such statement is based.
Statements concerning the development of the MRSA detector have
been made based on information obtained from Zenon Biosystem, which
the Company believes to be accurate, but have not been
independently verified.
Contact: Zenosense, Inc. Email: ir@zenosense.net Tel: +34 960
454 202 Web: www.zenosense.net
Zenosense Inc NV (CE) (USOTC:ZENO)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Zenosense Inc NV (CE) (USOTC:ZENO)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024